The best carnitine for your brain

  • Acetyl-L-Carnitine offers a better absorbed form of L-Carnitine
  • Provides cognitive support in neurological dysfunction
  • Helps relieve pain associated with diabetic neuropathy
Gluten Free

$39.94 or subscribe and save 20%

Out of stock

ALCAR is N-acetyl-L-carnitine, a form of L-carnitine found ubiquitously in mammalian tissues that is important for energy production. Extensive research has documented ALCAR’s ability to improve mitochondrial function, sperm production and energy production. ALCAR is unique because it is able to cross the blood-brain barrier more easily than L-carnitine, making it more effective for enhancing cognitive function. Research has found ALCAR to be capable of reducing the symptoms of mild cognitive impairment by improving memory, attention, mood and other cognitive functions. Amazingly, the positive cognitive effects seem to persist even after stopping short-term supplementation.

ALCAR can also increase L-carnitine levels in those who are deficient due to factors such as the use of certain medications, disease, a strict vegetarian diet, and heart or circulatory conditions. Some people use L-carnitine for athletic performance and endurance as it promotes energy production and proper fat burning. Muscle fatigue, male infertility (due to poor sperm health), Rett syndrome, chronic fatigue syndrome, anorexia, attention deficit-hyperactivity disorder (ADHD), thyroid imbalances, leg ulcers, high cholesterol and Lyme disease are all common conditions that may benefit from ALCAR supplementation.

ALCAR is beneficial for people of all walks of life including the young, middle-aged and elderly, vegetarians, infertility patients, brain rehab patients, those experiencing chronic fatigue and athletes. Since the benefits remain after one stops taking it, it is a worthwhile investment with good returns for anyone looking for additional memory, metabolic and general health support.

AOR Advantage

AOR’s Acetyl-L-Cartinitine can cross the blood-brain barrier and neural cell membranes more readily than conventional L-carnitine, making it more bioavailable. This particular ester also has numerous cognitive benefits associated with it that are not attributed to regular L-carnitine.




ALCAR is N-acetyl-L-carnitine, the form of L-carnitine that is the most abundant in the body. ALCAR readily crosses the blood-brain barrier and helps to reduce fatigue, support cognitive function in the elderly, maintain cognitive function during aging and even relieve pain associated with diabetic neuropathy.


AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal byproduct.

Adult Dosage

Take two to four capsules daily with food, or as directed by a qualified health care practitioner. A minimum of three months may be required before observing an effect.


This product provides 1.59 g of single amino acid per day. Consult a health care practitioner prior to use if you are pregnant, breastfeeding, have liver or kidney disease, have been instructed to follow a low protein diet, if symptoms persist or worsen or for use beyond six months. Feelings of overstimulation and/or sleeplessness may occur, in which case discontinue use if symptoms persist or worsen. Low incidence of seizures has been reported with oral doses in individuals with or without a pre-existing seizure disorder. Mild gastrointestinal symptoms (transient nausea, vomiting, abdominal cramps and diarrhea) have been reported. Body odour, flatulence, increased appetite or rash may occur.

Main Applications
  • Cognitive support
  • Neurological health
  • Chronic fatigue

The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.

Serving Size: One Capsule
N-Acetyl-L-Carnitine (HCl)
500 mg

Non-medicinal Ingredients: sodium stearyl fumarate. Capsule: hypromellose.

Cognitive Health:
Study 1:
Based on preliminary evidence from a multi-centered, double-blind, placebo-controlled study evaluating the effects of ALCAR on the cognitive deficits of alcoholics on at least one month of abstinence, researchers wanted to evaluate the effect of ALCAR supplementation in patients showing impaired performance in cognitive tasks. 55 patients were randomized to either a placebo group or ALCAR (2 g per day) for 90 days. Participants were assessed on neuropsychological battery exploring the areas of memory, constructional praxia, deductive-logical functions, and language, at time zero, after 45 days and after 90 days of supplementation. The results show a significant difference between the placebo group and ALCAR supplementation after 90 days in the memory and intelligence tests carried out. These results suggest that ALCAR supplementation has health benefits on cognitive function in chronic alcoholics.

Study 2:
Alzheimer’s disease (AD) does not have a cure. There are some options to assist with the symptoms of AD, as well as try to improve the quality of life of patients and caregivers. This randomized, double-blind, placebo-controlled, parallel-group study aimed to compare ALCAR and a placebo treatment in patients with dementia caused by AD. Participants were given either a placebo control medication or ALCAR (1 g twice daily) for 24 weeks, with assessments going on during the study. the results show a trend towards improvement in short-term memory assessments (Names learning and Computerized Digit Recall tests). Additionally, a positive trend in reaction time in the computerized classification test was observed in the ALCAR group, suggesting less cognitive deterioration, compared to the placebo group.

Study 3:
This study aimed to evaluate the distinct effects of acetyl- and propionyl-carnitine, alone and in combination in patients with mental fatigue and chronic fatigue syndrome in this open, randomized clinical trial. Participants were randomized to one of three groups: group one – 2 g/day acetyl-L-carnitine (ALCAR); group two – 2 g/day propionyl-L-carnitine (PLCAR); group three – combination group. Supplementation went on for 24 weeks and participants were monitored by the clinical global impression of change, multidimensional fatigue inventory, McGill pain questionnaire, and the Strrop attention concentration test. Each test was administered eight weeks before treatment commenced, at baseline and then after eight, 16, and 24 weeks of treatment and two weeks after treatment.

The results show that ALCAR and PLCAR individually improved symptoms of mental fatigue, attention, and concentration; however, the combination group appeared to do significantly worse than the individual treatment groups. The main critique of this study is a lack of positive or placebo control groups, which could be compared to the effect of each treatment group. Although there were no proper controls, it can be concluded that ALCAR and PLCAR have a beneficial effect on fatigue and attention concentration, with ALCAR showing more of an effect on mental fatigue, while PLCAR has more of an effect on general fatigue.

Another study, published later, just looked at the effect of ALCAR in elderly patients with fatigue, where they show that supplementation with ALCAR was associated with a reduction in both physical and mental fatigue while improving both cognitive status and physical functions.

Study 4:
In this double-blind, placebo-controlled, parallel-group, randomized study, the researchers evaluated the efficacy of long term use of ALCAR in patients with a clinical diagnosis of Alzheimer’s disease (AD). 130 patients were given either a placebo or ALCAR daily for a year and employed 14 outcome measures to assess functional and cognitive impairment. The results show that ALCAR supplementation slowed the rate of deterioration in 13 of the 14 outcomes measures, suggesting a beneficial role of ALCAR in cognitive improvement and quality of life in AD patients.

Blood Glucose & Insulin Sensitivity:
Study 1:
In this open, blind end-point, longitudinal, sequential off-on-off, prospective, pilot study, the effect of ALCAR supplementation on increased cardiovascular risk was observed. Non-diabetic subjects at an increased risk for cardiovascular diseases were recruited for this study and were supplemented with 1g ALCAR twice daily for 24 weeks. Patients were assessed for glucose disposal rate (GDR) and blood pressure markers at intervals during the study. Baseline GDR and systolic blood pressure were negatively correlated with ALCAR supplementation. Lower GDR was also associated with improved glucose tolerance, suggesting that ALCAR supplementation can help reduce arterial hypertension, improve insulin resistance, impaired glucose tolerance, and hypoadiponectinemia in subjects at increased cardiovascular risk.

Study 2:
This randomized, placebo-controlled, double-blinded study aimed to determine the effects of ALCAR supplementation on resting and postprandial biomarkers of glucose and lipid metabolism, as well as oxidative stress. Pre-diabetic subjects were randomized to placebo or ALCAR (3 g per day) supplementation group and fasting blood samples were taken from subjects both pre and post-intervention. After each fasting sample was obtained, subjects consumed a high fat, high carbohydrate meal, and additional blood samples were taken at one, two, four, and six hours post-meal. Samples were analyzed for a variety of metabolic variables (e.g., glucose, HbA1c, lipid panel, C-reactive protein, nitrate/nitrite, and several markers of oxidative stress).

ALCAR supplementation resulted in an increase in nitrate/nitrite levels, improvements in glucose, Hb1AC, and HOMA-IR levels from pre to post-intervention and in comparison to the placebo group.

Study 3:
The aim of this randomized controlled study was to explore the role of L-carnitine supplementation in influencing insulin sensitivity in patients with impaired fasting glucose or type II diabetes. Within 10 days of diagnosis, patients meeting the inclusion criteria were recruited for the study. Patients were randomly assigned to receive a hypocaloric diet for 10 days or the same dietetic regimen in addition to oral L-carnitine (2 g twice daily) supplementation. Oral glucose tolerance test (OGTT), fasting plasma insulin levels, and homeostasis model assessment of insulin resistance (HOMA-IR) was assessed at the beginning and end of the study.

Results showed that L-carnitine supplementation as associated with a reduction in plasma insulin levels and HOMA-IR, compared to the diet alone and baseline values. This suggests that L-carnitine supplementation, along with caloric restriction could improve insulin resistance in patients with impaired fasting glucose and type II diabetes.

Study 4:
The effect of carnitine supplementation on non-oxidative glucose disposal has been established in several pre-clinical research models. This study aimed to take this a little farther, by evaluating the effect of oral carnitine supplementation on glucose disposal in non-diabetic versus overweight/obese males. Following supplementation of either a placebo or L-carnitine (3 g/day) for 14 days, study participants were assessed for the effect supplementation on blood glucose, insulin, non-esterified fatty acids (NEFA) and total glucagon-like peptide-1 (GLP-1) responses.

Significant differences were observed between the placebo and supplementation groups on the following assessed endpoints: Although there was also a significant difference in the responses of the lean and overweight participants, a significant decrease in plasma glucose concentration in both groups, which was not dependent on the GLP-1.

Study 5:
The aim of this study was to assess the effect of L-carnitine supplementation on plasma lipids and expression of enzymes involved in the regulation of fatty acid and glucose oxidation, as a way to determine the effect of this supplementation on insulin resistance. Patients were given L-carnitine (2 g/day) and then blood samples were obtained for analysis. The results show a significant decrease in free fatty acids and plasma triglycerides. This finding was important, as increased free fatty acids are hypothesized to be one of the main causes of insulin resistance and consequently gestational diabetes.

Study 6:
In this analysis of two randomized, placebo-controlled clinical trials, the authors sought to evaluate the effect of two doses of long-term ALCAR supplementation in patients with clinical diabetic neuropathy. Patients received either a placebo, 500 mg, or 1000 mg ALCAR three times a day for 52 weeks and they were assessed for sural nerve morphometry, nerve conduction velocities, cibration perception thresholds, clinical symptom scores and a visual analog scale (VAS) for pain.
The results from both studies and the analysis showed significant improvements in sural nerve fiber numbers and regenerating nerve fiber clusters, as well as vibration perception. In this study giving 1000 mg ALCAR three times daily, a reduction in pain was also observed, demonstrating that ALCAR effectively reduces pain and improves nerve fiber regeneration and vibration perception in diabetic patients, suffering neuropathy.

Cardiovascular Health:
Study 1:
The L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) clinical trial was a double-blind, randomized, placebo-controlled, multicenter study that evaluated the effects of L-carnitine supplementation on long-term ventricular dilation in patients with acute anterior myocardial infarctions. 472 patients with a first acute myocardial infarction were randomized to receive either a placebo or L-carnitine (9 g/day intravenous for the first five days, followed by 6 g/day oral administration for the next 12 months). Left ventricular volumes and ejection fraction was evaluated on admission, at discharge from hospital and at three, six, and 12 months after acute myocardial infarction.
A significant reduction in left ventricular dilation in the first year after myocardial infarction was observed in the L-carnitine supplementation group, compared to the placebo. In addition, a significant reduction in the high end-diastolic and systolic volumes was observed with supplementation, suggesting that L-carnitine supplementation could promote heart health and recovery after acute myocardial infarction.

Study 2:
In this open, blind end-point, longitudinal, sequential off-on-off, prospective, pilot study, the effect of ALCAR supplementation on increased cardiovascular risk was observed. Non-diabetic subjects at an increased risk for cardiovascular diseases were recruited for this study and were supplemented with 1 g ALCAR twice daily for 24 weeks. Patients were assessed for glucose disposal rate (GDR) and blood pressure markers at intervals during the study. Baseline GDR and systolic blood pressure were negatively correlated with ALCAR supplementation. Lower GDR was also associated with improved glucose tolerance, suggesting that ALCAR supplementation can help reduce arterial hypertension, improve insulin resistance, impaired glucose tolerance, and hypoadiponectinemia in subjects at increased cardiovascular risk.

Study 3:
This systematic review and meta-analysis evaluated the effects of L-carnitine and ALCAR supplementation, in comparison with a control, on mortality and morbidity in the settings of acute myocardial infarctions. This review included 13 controlled trials, with a participant population of 3629 and the following endpoints were included in the analysis: mortality, ventricular arrhythmias (VAs), angina, heart failure, and reinfarction.

Compared with placebo or control, L-carnitine was associated with a significant 27% reduction in all-cause mortality, a highly significant 65% reduction in VAs, and a significant 40% reduction in the development of angina in patients with acute myocardial infarction.

Athletic/Exercise Performance:
The human clinical studies on carnitine supplementation and their effects on athletic performance and exercise recovery involve the use of L-carnitine tartrate as the form of carnitine. This molecule is critical for normal skeletal muscle bioenergetics, because of its dual role in fatty acid transport and oxidation and mitochondrial energy production; both processes are required for exercise performance and peak muscle effects.

One blinded, placebo-controlled, randomized study of L-carnitine supplementation, shows increased running speeds, reduction in heart rate, and prolonged time to exhaustion in the supplemented group, compared to the control group

A balanced, crossover clinical study looked at exercise-induced biomarkers in resistance-trained men, consuming either a placebo or L-carnitine, which showed the effectiveness of carnitine supplementation in assisting in recovery in participants carrying out high repetition squat exercises

Finally, this single-blind crossover study looked at the effect of L-carnitine supplementation on pain, tenderness, and cytokine release induced by exercise. 3 g per day L-carnitine supplementation was associated with a significant reduction in pain, tenderness, and cytokine release, compared to the placebo control. The researchers conclude that L-carnitine has a protective effect against pain and damage from exercise and this effect is attributed to the vasodilation property of L-carnitine

Although these studies are looking at the effect of L-carnitine supplementation, it is not difficult to extrapolate this effect on other forms of carnitine, including the acetylated ALCAR. This molecule is highly bioavailable, can cross the blood-brain barrier, and has the same effects on fatty acid transport and oxidation, as well as mitochondrial bioenergetics. These processes are essential for muscle health and energy production.×300-0/l_carnitine_base_hcl_tartrate_fumarate_acetyl_l_carnitine_hcl_for.jpg